New York State Common Retirement Fund Sells 3,622 Shares of Glaukos Corporation (NYSE:GKOS)

New York State Common Retirement Fund trimmed its position in shares of Glaukos Corporation (NYSE:GKOS - Free Report) by 0.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 377,666 shares of the medical instruments supplier's stock after selling 3,622 shares during the period. New York State Common Retirement Fund owned approximately 0.66% of Glaukos worth $37,170,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Raymond James Financial Inc. bought a new stake in shares of Glaukos in the 4th quarter valued at approximately $16,910,000. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Glaukos by 36.4% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,939 shares of the medical instruments supplier's stock valued at $2,240,000 after purchasing an additional 3,983 shares during the period. HighTower Advisors LLC boosted its holdings in shares of Glaukos by 2.8% in the 4th quarter. HighTower Advisors LLC now owns 3,298 shares of the medical instruments supplier's stock worth $495,000 after acquiring an additional 91 shares in the last quarter. Swiss National Bank boosted its holdings in shares of Glaukos by 9.9% in the 4th quarter. Swiss National Bank now owns 108,100 shares of the medical instruments supplier's stock worth $16,209,000 after acquiring an additional 9,700 shares in the last quarter. Finally, Commonwealth Equity Services LLC boosted its holdings in shares of Glaukos by 12.9% in the 4th quarter. Commonwealth Equity Services LLC now owns 5,770 shares of the medical instruments supplier's stock worth $865,000 after acquiring an additional 661 shares in the last quarter. 99.04% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have recently commented on GKOS shares. BTIG Research reissued a "buy" rating on shares of Glaukos in a report on Monday. Stifel Nicolaus reduced their price objective on Glaukos from $140.00 to $115.00 and set a "buy" rating on the stock in a report on Thursday, May 1st. Mizuho reduced their price objective on Glaukos from $200.00 to $175.00 and set an "outperform" rating on the stock in a report on Wednesday, April 16th. Truist Financial reaffirmed a "buy" rating and set a $135.00 price objective (down previously from $140.00) on shares of Glaukos in a report on Thursday, May 1st. Finally, Needham & Company LLC cut their price target on Glaukos from $176.00 to $115.00 and set a "buy" rating on the stock in a research note on Thursday, May 1st. One analyst has rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the company. According to MarketBeat.com, Glaukos presently has a consensus rating of "Moderate Buy" and an average price target of $134.67.

Glaukos Stock Down 0.7%

GKOS stock traded down $0.70 during trading hours on Friday, reaching $98.30. 255,993 shares of the stock were exchanged, compared to its average volume of 746,939. The firm's 50-day moving average is $98.13 and its 200-day moving average is $113.02. Glaukos Corporation has a 12 month low of $77.10 and a 12 month high of $163.71. The company has a debt-to-equity ratio of 0.09, a current ratio of 6.49 and a quick ratio of 5.62. The company has a market cap of $5.62 billion, a price-to-earnings ratio of -41.48 and a beta of 0.82.

Glaukos (NYSE:GKOS - Get Free Report) last issued its earnings results on Wednesday, April 30th. The medical instruments supplier reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.11. The business had revenue of $106.66 million during the quarter, compared to the consensus estimate of $102.78 million. Glaukos had a negative net margin of 31.40% and a negative return on equity of 10.66%. Glaukos's revenue was up 24.6% on a year-over-year basis. During the same period last year, the business posted ($0.70) EPS. On average, equities research analysts expect that Glaukos Corporation will post -1.08 earnings per share for the current year.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.